ClinicalTrials.gg
CompletedNCT01710709ATLASUpdated Sep 21, 2018Results posted

Open-label Study to Evaluate the Effectiveness of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients With Bipolar I Disorder

A Phase 3 interventional study of Aripiprazole in Bipolar I, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 142 sites in 10 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2018-09-21.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
748
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This will be an open-label uncontrolled trial to evaluate the safety and tolerability of aripiprazole IM depot administered every 4 weeks for up to 52 weeks to patients with bipolar I disorder. The trial will enroll subjects who completed Trial 31-08-250 and de novo subjects not participating in Trial 31-08-250.

Read the detailed description

This will be an open-label, uncontrolled study which will enroll subjects completing Study 31-08-250 and new subjects. The treatment history of subjects prior to enrollment in the open-label study will vary according to the design of the pivotal double-blind study (i.e 31-08-250).

This open-label study will be comprised of phases similar to the pivotal double-blind study (i.e. Study 250): a screening phase (if applicable), a conversion phase (Phase A, if applicable), an oral stabilization phase (Phase B, if applicable), and an IM depot open-label maintenance phase (Phase C). Phase C will be a minimum of 28 weeks up to a 52-week treatment period with a 4 week follow up period.

During Phase C (the open-label maintenance phase) rescue medication will be allowed for subjects who do not meet stability criteria. This analysis focuses on Phase C due to ClinicalTrials.gov system limitations.

02

Conditions studied

  • Bipolar I

Keywords

  • Aripiprazole, Intramuscular (IM) Depot, Bipolar
03

In context

Lead sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.

Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Completed participation in Trial 31-08-250
  • De novo subjects not participating in Trial 31-08-250
  • Subjects who are able to provide written .
  • Male and female subjects 18 years of age or older at time of informed consent
  • Subjects who, in the investigator's judgment, require chronic treatment with an antipsychotic medication for their bipolar I disorder and would benefit from extended treatment with a long-acting injectable formulation
  • Subjects who have a recurrence of mood episode or exacerbations of mood symptoms when they are not receiving treatment for their bipolar I disorder or are noncompliant with treatment for their bipolar I disorder
  • Have an outpatient status

Exclusion criteria

Exclusion Criteria:

  • Experienced 9 or more mood episodes within the past year
  • A current manic episode with a duration of > 2 years
  • Currently meet criteria for substance abuse or substance dependence; this includes the abuse of alcohol and benzodiazepines, but excludes the use of caffeine and/or nicotine
  • Hypothyroidism or hyperthyroidism, unless condition has been stabilized
  • Diagnosed with epilepsy or a history of seizures
  • Known to be allergic, intolerant, or unresponsive to prior treatment with aripiprazole or other quinolinones
  • Sexually active women of and sexually active men who will not commit to utilizing 2 of the approved methods or who will not remain abstinent during this trial and for 180 days following the last dose of trial medication
  • Females breastfeeding or pregnant (positive blood pregnancy test prior to receiving trial drug)
  • Risk of committing suicide
  • Abnormal laboratory test results, vital signs and results
  • Participated in any clinical trial other than Trial 250 with an agent within the 30 days prior to screening
  • Had electroconvulsive therapy (ECT) treatment during the current episode or within 3 months
  • Subjects who have not met criteria for stabilization for 4 consecutive weeks
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
748 participants (actual)

Study arms

  • Experimental
    Experimental

    Aripiprazole, Intramuscular (IM) Depot

    Drug: Aripiprazole

Interventions

  • 400mg or 300mg, intramuscular injections every 4 weeks.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events

    An adverse event (AE) is defined as any untoward medical occurrence in a patient or participant enrolled in the clinical trial and which does not necessarily have to have a causal relationship with the investigational medicinal product (IMP). AEs were assessed as a criteria for safety and tolerability.

    Time frame: Up to Week 52

  2. Injection Site Pain Measured by the Visual Analog Scale (VAS)

    Injection-site pain was evaluated by mean visual analog scale (VAS) scores as reported by the participant after each injection at visits where an injection occurred. Ratings ranged from 0 (no pain) to 100 (unbearably painful).

    Time frame: Up to Week 52

  3. Number of Participants With Clinically Significant Abnormal Laboratory Test Results

    Standard safety variables to be analyzed included clinical laboratory tests. Incidence of treatment emergent adverse events (TEAEs) of potential clinical relevance included abnormal values in serum chemistry, hematology, urinalysis, and other laboratory test that were identified based on pre-defined criteria. Abnormal laboratory values in participants were reported as serious adverse event/adverse events (SAE/AEs) and are reported in the SAE/other AE section of this report.

    Time frame: Up to Week 52

  4. Number of Participants With Clinically Significant Abnormal Vital Signs

    TEAEs of potential clinical relevance included abnormal values in body weight, systolic and diastolic blood pressure, heart rate, and body temperature that were identified based on pre-defined criteria. Abnormal laboratory values in participants were reported as SAE/AEs and are reported in the SAE/other AE section of this report.

    Time frame: Up to Week 52

  5. Number of Participants With Clinically Significant Abnormal Electrocardiogram (ECGs)

    Twelve-lead ECGs were recorded at specified visits. For each time point, three 12-lead ECG recordings were obtained approximately 5 minutes apart. Additional 12-lead ECGs were permitted to be obtained at the investigator's discretion and were to always be obtained in the event of an early termination. The ECGs were evaluated at the investigational site to determine the participant's eligibility and to monitor safety during the trial.

    Time frame: Up to Week 52

  6. Extrapyramidal Symptoms Will be Assessed by Mean Change From Baseline on Abnormal Involuntary Movement Scale(AIMS), Simpson-Angus Scale (SAS), Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS Only Used in Japan) and Barnes Akathisia Rating Scale (BARS)

    AIMS: 10 items described dyskinesia signs; 0-absence/no awareness; 4-severe condition/severe distress. Total score for Items 1-10 ranges from 0 to 40; a higher score reflects severe condition. SAS:Consisted of 10 parkinsonism signs;1-no symptoms;5-severe.Total score for Items 1-10 ranges from 1 to 50;a higher score reflects severe condition.DIEPSS:A 9-item rating scale (8 assessed individual symptoms \[4 categories of parkinsonism, akathisia, dystonia \& dyskinesia\]+1 assessed general severity) was used;0-no symptoms/normal, 4-severe.Total score (8 individual symptom items) was in range of 0 to 32 (a higher score reflects severe condition).BARS:Consisted of 4 items related to akathisia:objective observation, subjective feelings of restlessness, distress, global clinical evaluation.Only BARS global clinical assessment score has been presented and rated using scale:0-absence of symptoms;5-severe akathisia.Total BARS global score ranges from 0 to 5,a higher score reflects severe condition.

    Time frame: Baseline, Week 28, and Week 52

  7. Number of Participants Experiencing Suicidal Events and Their Classification According to the Completion of Columbia Suicide Severity Rating Scale (C-SSRS)

    Suicidality was monitored throughout the trial using the C-SSRS at every visit. The C-SSRS scale consisted of a screening/baseline evaluation that assessed the participant's lifetime experience and experience over the last 90 days with suicide events and suicidal ideation and a post-baseline/ "Since Last Visit" evaluation that focused on suicidality since the last trial visit.

    Time frame: Up to Week 52

  8. Number of Participants With Injection Site Evaluations (Pain, Redness, Swelling, Induration) Measured by Investigator Rating

    Injection-site reactions were assessed by the investigator (or qualified designee) and the participant. Investigators rated localized pain, redness, swelling, and induration at the most recent injection site using a 4-point categorical scale (absent, mild, moderate, severe) . The participant indicated the degree of pain at the most recent injection site using a VAS. Ratings ranged from 0 (no pain) to 100 (unbearably painful). Ratings included were: 0 = absent, 1 = mild, 2 = moderate, 3 = severe. These assessments occurred at trial visits where injections occurred (scheduled and unscheduled), beginning with the first dose of open-label aripiprazole IM depot administered at the final visit of the Oral Stabilization Phase and continued through the last injection prior to the end of the IM Depot Maintenance Phase/Early termination (ET) visit (ie, evaluations were not done at end of the IM Depot Maintenance Phase/ET visit).

    Time frame: Up to Week 52

Secondary outcomes

  1. Percentage of Participants Who Remained Stable at End of Treatment in Phase C

    The secondary objective was to evaluate the efficacy, as measured by the percentage of stable participants at baseline who remained stable at the end of treatment in the IM depot maintenance phase, of aripiprazole IM depot administered every 4 weeks for up to 52 weeks to subjects with bipolar I disorder.

    Time frame: Up to Week 52

07

Results

Posted Aug 8, 2018

Participant flow

This open-label, single-arm, uncontrolled trial evaluated aripiprazole intramuscular (IM) depot as maintenance treatment for participants with bipolar I disorder. Enrolled participants included those who had completed Trial 31-08-250 (NCT01567527) as well as de novo participants who had not participated in Trial 31-08-250.

Participant flow — Overall Study
MilestonePhase C: Open-Label IM Depot Maintenance Phase
Started464
Completed291
Not completed173
Withdrew: Lost to follow-up29
Withdrew: Adverse event48
Withdrew: Participant met withdrawal criteria33
Withdrew: Participant withdrawn by investigator2
Withdrew: Withdrawal by subject53
Withdrew: Protocol violation5
Withdrew: Lack of efficacy3

Outcome measures

PrimaryNumber of Participants With Adverse Events

An adverse event (AE) is defined as any untoward medical occurrence in a patient or participant enrolled in the clinical trial and which does not necessarily have to have a causal relationship with the investigational medicinal product (IMP). AEs were assessed as a criteria for safety and tolerability.

Time frame:
Up to Week 52
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsPhase C: Open-label IM Depot Maintenance Phase
Participants with adverse events374
Participants with TEAEs374
Participants with serious TEAEs30
Participants with severe TEAEs41
Participants discontinued from IMP due to AEs47
Participants discont. from IMP due to AEs or death48
Deaths1
PrimaryInjection Site Pain Measured by the Visual Analog Scale (VAS)

Injection-site pain was evaluated by mean visual analog scale (VAS) scores as reported by the participant after each injection at visits where an injection occurred. Ratings ranged from 0 (no pain) to 100 (unbearably painful).

Time frame:
Up to Week 52
Reported as:
Mean · Units on a scale
Injection Site Pain Measured by the Visual Analog Scale (VAS)
Units on a scalePhase C: Open-label IM Depot Maintenance Phase
1ST Injection4.9 ± 10.7
2ND Injection4.1 ± 8.4
3RD Injection3.4 ± 7.5
4TH Injection3.6 ± 8.6
5TH Injection2.9 ± 7.9
6TH Injection2.4 ± 5.8
7TH Injection2.6 ± 7.0
8TH Injection2.4 ± 4.9
9TH Injection2.6 ± 6.6
10TH Injection2.5 ± 7.5
11TH Injection2.4 ± 6.3
12TH Injection1.8 ± 4.3
13TH Injection2.2 ± 5.5
Last Injection2.4 ± 5.9
PrimaryNumber of Participants With Clinically Significant Abnormal Laboratory Test Results

Standard safety variables to be analyzed included clinical laboratory tests. Incidence of treatment emergent adverse events (TEAEs) of potential clinical relevance included abnormal values in serum chemistry, hematology, urinalysis, and other laboratory test that were identified based on pre-defined criteria. Abnormal laboratory values in participants were reported as serious adverse event/adverse events (SAE/AEs) and are reported in the SAE/other AE section of this report.

Time frame:
Up to Week 52
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormal Laboratory Test Results
ParticipantsPhase C: Open-label IM Depot Maintenance Phase
Fasting cholesterol53
Fasting glucose39
Fasting low-density lipoprotein cholesterol32
Fasting triglycerides124
PrimaryNumber of Participants With Clinically Significant Abnormal Vital Signs

TEAEs of potential clinical relevance included abnormal values in body weight, systolic and diastolic blood pressure, heart rate, and body temperature that were identified based on pre-defined criteria. Abnormal laboratory values in participants were reported as SAE/AEs and are reported in the SAE/other AE section of this report.

Time frame:
Up to Week 52
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormal Vital Signs
ParticipantsPhase C: Open-label IM Depot Maintenance Phase
Weight gain of ≥ 7%93
Weight loss of ≥ 7%66
Blood pressure increased4
Heart rate increased3
Blood pressure decreased2
Body temperature0
PrimaryNumber of Participants With Clinically Significant Abnormal Electrocardiogram (ECGs)

Twelve-lead ECGs were recorded at specified visits. For each time point, three 12-lead ECG recordings were obtained approximately 5 minutes apart. Additional 12-lead ECGs were permitted to be obtained at the investigator's discretion and were to always be obtained in the event of an early termination. The ECGs were evaluated at the investigational site to determine the participant's eligibility and to monitor safety during the trial.

Time frame:
Up to Week 52
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormal Electrocardiogram (ECGs)
ParticipantsPhase C: Open-label IM Depot Maintenance Phase
Symmetrical T-wave inversion9
Supraventricular premature beat8
Ventricular premature beat4
Myocardial ischemia2
PrimaryExtrapyramidal Symptoms Will be Assessed by Mean Change From Baseline on Abnormal Involuntary Movement Scale(AIMS), Simpson-Angus Scale (SAS), Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS Only Used in Japan) and Barnes Akathisia Rating Scale (BARS)

AIMS: 10 items described dyskinesia signs; 0-absence/no awareness; 4-severe condition/severe distress. Total score for Items 1-10 ranges from 0 to 40; a higher score reflects severe condition. SAS:Consisted of 10 parkinsonism signs;1-no symptoms;5-severe.Total score for Items 1-10 ranges from 1 to 50;a higher score reflects severe condition.DIEPSS:A 9-item rating scale (8 assessed individual symptoms \[4 categories of parkinsonism, akathisia, dystonia \& dyskinesia\]+1 assessed general severity) was used;0-no symptoms/normal, 4-severe.Total score (8 individual symptom items) was in range of 0 to 32 (a higher score reflects severe condition).BARS:Consisted of 4 items related to akathisia:objective observation, subjective feelings of restlessness, distress, global clinical evaluation.Only BARS global clinical assessment score has been presented and rated using scale:0-absence of symptoms;5-severe akathisia.Total BARS global score ranges from 0 to 5,a higher score reflects severe condition.

Time frame:
Baseline, Week 28, and Week 52
Reported as:
Mean · Units on a scale
Extrapyramidal Symptoms Will be Assessed by Mean Change From Baseline on Abnormal Involuntary Movement Scale(AIMS), Simpson-Angus Scale (SAS), Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS Only Used in Japan) and Barnes Akathisia Rating Scale (BARS)
Units on a scalePhase C: Open-label IM Depot Maintenance Phase
AIMS, Week 280.07 ± 1.00
AIMS, Week 520.05 ± 0.97
SAS, Week 280.21 ± 1.59
SAS, Week 520.20 ± 1.58
DIEPSS, Week 280.32 ± 1.29
DIEPSS, Week 520.21 ± 1.11
BARS, Week 280.05 ± 0.61
BARS, Week 520.04 ± 0.60
PrimaryNumber of Participants Experiencing Suicidal Events and Their Classification According to the Completion of Columbia Suicide Severity Rating Scale (C-SSRS)

Suicidality was monitored throughout the trial using the C-SSRS at every visit. The C-SSRS scale consisted of a screening/baseline evaluation that assessed the participant's lifetime experience and experience over the last 90 days with suicide events and suicidal ideation and a post-baseline/ "Since Last Visit" evaluation that focused on suicidality since the last trial visit.

Time frame:
Up to Week 52
Reported as:
Count of participants · Participants
Number of Participants Experiencing Suicidal Events and Their Classification According to the Completion of Columbia Suicide Severity Rating Scale (C-SSRS)
ParticipantsPhase C: Open-label IM Depot Maintenance Phase
Completed Suicide0
Suicide Attempt3
Preparatory action toward imminent suicide4
Suicidal ideation46
Non-suicidal self-injurious behavior4
PrimaryNumber of Participants With Injection Site Evaluations (Pain, Redness, Swelling, Induration) Measured by Investigator Rating

Injection-site reactions were assessed by the investigator (or qualified designee) and the participant. Investigators rated localized pain, redness, swelling, and induration at the most recent injection site using a 4-point categorical scale (absent, mild, moderate, severe) . The participant indicated the degree of pain at the most recent injection site using a VAS. Ratings ranged from 0 (no pain) to 100 (unbearably painful). Ratings included were: 0 = absent, 1 = mild, 2 = moderate, 3 = severe. These assessments occurred at trial visits where injections occurred (scheduled and unscheduled), beginning with the first dose of open-label aripiprazole IM depot administered at the final visit of the Oral Stabilization Phase and continued through the last injection prior to the end of the IM Depot Maintenance Phase/Early termination (ET) visit (ie, evaluations were not done at end of the IM Depot Maintenance Phase/ET visit).

Time frame:
Up to Week 52
Reported as:
Count of participants · Participants
Number of Participants With Injection Site Evaluations (Pain, Redness, Swelling, Induration) Measured by Investigator Rating
ParticipantsPhase C: Open-label IM Depot Maintenance Phase
Injection Site Bruising2
Injection Site Erythema1
Injection Site Induration1
Injection Site Mass2
Injection Site Pain34
Injection Site Swelling4
SecondaryPercentage of Participants Who Remained Stable at End of Treatment in Phase C

The secondary objective was to evaluate the efficacy, as measured by the percentage of stable participants at baseline who remained stable at the end of treatment in the IM depot maintenance phase, of aripiprazole IM depot administered every 4 weeks for up to 52 weeks to subjects with bipolar I disorder.

Time frame:
Up to Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants Who Remained Stable at End of Treatment in Phase C
Percentage of participantsPhase C: Open-label IM Depot Maintenance Phase
Baseline100.00
Week 296.98
Week 497.22
Week 895.64
Week 1296.31
Week 1696.46
Week 2095.54
Week 2496.40
Week 2895.09
Week 3297.91
Week 3695.94
Week 4098.04
Week 4497.59
Week 4897.53
Week 5295.78
Last Visit88.91

Adverse events

Collected over Phase C week 1 to week 52/early termination.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase C: Open-Label IM Depot Maintenance Phase1/464 (0.2%)30/464 (6.5%)367/464 (79.1%)
Most frequent serious events
Showing 10 of 24
Most frequent serious events
EventPhase C: Open-Label IM Depot Maintenance Phase
Bipolar I DisorderPsychiatric disorders4/464
Suicidal IdeationPsychiatric disorders4/464
ManiaPsychiatric disorders3/464
Chest PainGeneral disorders2/464
Bipolar DisorderPsychiatric disorders2/464
Acute Myocardial InfarctionCardiac disorders1/464
Cardiac ArrestCardiac disorders1/464
Myocardial InfarctionCardiac disorders1/464
Prinzmetal AnginaCardiac disorders1/464
HyperprolactinaemiaEndocrine disorders1/464
Most frequent other events
Showing 10 of 11
Most frequent other events
EventPhase C: Open-Label IM Depot Maintenance Phase
AkathisiaNervous system disorders68/464
Weight increasedInvestigations62/464
NasopharyngitisInfections and infestations56/464
InsomniaPsychiatric disorders51/464
AnxietyPsychiatric disorders46/464
Injection site painGeneral disorders34/464
HeadacheNervous system disorders29/464
TremorNervous system disorders28/464
DepressionPsychiatric disorders26/464
Upper respiratory tract infectionInfections and infestations24/464

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Phase C: Open-label IM Depot Maintenance Phase
<=18 years0
Between 18 and 65 years458
>=65 years6
Age, Continuous
Age, Continuous(Years)Phase C: Open-label IM Depot Maintenance Phase
Mean41.1 ± 11.8
Sex: Female, Male
Sex: Female, Male(Participants)Phase C: Open-label IM Depot Maintenance Phase
Female268
Male196
Region of Enrollment
Region of Enrollment(Participants)Phase C: Open-label IM Depot Maintenance Phase
Canada3
South Korea6
Romania10
Hungary4
United States322
Japan75
Taiwan1
Poland28
Malaysia10
France5
08

Study locations

142 sites
  • Birmingham, Alabama 35226, United States
  • Little Rock, Arkansas 72211, United States
  • Rogers, Arkansas 72758, United States
  • Bellflower, California 90706, United States
  • Beverly Hills, California 90210, United States
  • Costa Mesa, California 92626, United States
  • Culver City, California 90230, United States
  • Garden Grove, California 92845, United States
  • Lemon Grove, California 91945, United States
  • Oakland, California 94607, United States
  • Orange, California 92868, United States
  • Pico Rivera, California 90660, United States
  • Riverside, California 92506, United States
  • San Diego, California 92102, United States
  • Temecula, California 92591, United States
  • Upland, California 91786, United States
  • Wildomar, California 92595, United States
  • Colorado Springs, Colorado 80910, United States
  • Gainesville, Florida 32607, United States
  • Hialeah, Florida 33012, United States
  • Jacksonville, Florida 32256, United States
  • Leesburg, Florida 34748, United States
  • Orlando, Florida 32801, United States
  • Tampa, Florida 33613, United States
  • Atlanta, Georgia 30331, United States
  • Decatur, Georgia 30030, United States
  • Smyrna, Georgia 30080, United States
  • Chicago, Illinois 60611, United States
  • Chicago, Illinois 60612, United States
  • Hinsdale, Illinois 60522, United States
  • Naperville, Illinois 60563, United States
  • Schaumburg, Illinois 60194, United States
  • Prairie Village, Kansas 66206, United States
  • Lake Charles, Louisiana 70629, United States
  • Baltimore, Maryland 21208, United States
  • Gaithersburg, Maryland 20877, United States
  • Boston, Massachusetts 02131, United States
  • O'Fallon, Missouri 63368, United States
  • Saint Louis, Missouri 63128, United States
  • Lincoln, Nebraska 68526, United States
  • Berlin, New Jersey 08009, United States
  • Cherry Hill, New Jersey 08002, United States
  • Brooklyn, New York 11241, United States
  • Buffalo, New York 14215, United States
  • New York, New York 10003, United States
  • New York, New York 10023, United States
  • Rochester, New York 14615, United States
  • Rochester, New York 14618, United States
  • Staten Island, New York 10305, United States
  • Staten Island, New York 10312, United States
  • Cincinnati, Ohio 45219, United States
  • Oklahoma City, Oklahoma 73103, United States
  • Oklahoma City, Oklahoma 73112, United States
  • Oklahoma City, Oklahoma 73118, United States
  • Portland, Oregon 97210, United States
  • Allentown, Pennsylvania 18104, United States
  • Media, Pennsylvania 19063, United States
  • Columbia, South Carolina 29201, United States
  • Memphis, Tennessee 38119, United States
  • Arlington, Texas 76012, United States
  • Austin, Texas 78754, United States
  • Dallas, Texas 75243, United States
  • Plano, Texas 75074, United States
  • Plano, Texas 75093, United States
  • Sugar Land, Texas 77478, United States
  • Wichita Falls, Texas 76309, United States
  • Orem, Utah 84058, United States
  • Salt Lake City, Utah 84106, United States
  • Richmond, Virginia 23230, United States
  • Bellevue, Washington 98007, United States
  • Spokane, Washington 99204, United States
  • Middleton, Wisconsin 53562, United States
  • Kentville, Nova Scotia B4N 4K9, Canada
  • Chatham, Ontario N7L 1C1, Canada
  • Elancourt, 78990, France
  • Limoges, 87025, France
  • Nimes, 30900, France
  • Toulouse, 31000, France
  • Budapest, H-1135, Hungary
  • Nyireghaza, H-4400, Hungary
  • Vac, H-2600, Hungary
  • Fukuoka, 814-0133, Japan
  • Fukuoka, 819-0037, Japan
  • Fukuoka, 830-0033, Japan
  • Fukushima, 960-0102, Japan
  • Fukushima, 961-0021, Japan
  • Fukushima, 963-0207, Japan
  • Gunma, 375-0017, Japan
  • Gunma, 377-0055, Japan
  • Ibaraki, 311-3193, Japan
  • Ibaraki, 319-1221, Japan
  • Iizuka, 820-0014, Japan
  • Kanagawa, 216-8511, Japan
  • Kanagawa, 221-0801, Japan
  • Kanagawa, 223-0062, Japan
  • Kanagawa, 225-0003, Japan
  • Kanagawa, 238-0042, Japan
  • Kanagawa, 259-1304, Japan
  • Kochi, 783-8505, Japan
  • Kouchi, 780-0062, Japan

Showing the first 100 of 142 sites across 10 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Calabrese JR, Jin N, Johnson B, Such P, Baker RA, Madera J, Hertel P, Ottinger J, Amatniek J, Kawasaki H. Aripiprazole once-monthly as maintenance treatment for bipolar I disorder: a 52-week, multicenter, open-label study. Int J Bipolar Disord. 2018 Jun 10;6(1):14. doi: 10.1186/s40345-018-0122-z. PubMed 29886522 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2012, a primary completion of Nov 2016 and a completion of Dec 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2018, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2012
First posted
Oct 19, 2012
Start
Nov 2012
Primary completionActual
Nov 2016
CompletionActual
Dec 2016
Results first posted
Aug 8, 2018
Last update
Sep 21, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01710709
Collaborators
H. Lundbeck A/S
Responsible party
Sponsor
First posted
Oct 19, 2012
Start date
Nov 2012
Primary completion
Nov 2016
Completion
Dec 2016
Results posted
Aug 8, 2018
Last update
Sep 21, 2018

Study contacts

Joan Amatniek, MD
study director · Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aripiprazole

Start the discussion